Regeneron Pharmaceuticals
Stock Forecast, Prediction & Price Target
Regeneron Pharmaceuticals (REGN) stock Price Target by analysts
Regeneron Pharmaceuticals (REGN) stock Price Target by analysts
Average Price Target
$1,110
Potential upside: 93.11%
Regeneron Pharmaceuticals price prediction
What is Regeneron Pharmaceuticals stock analysts` prediction?
Regeneron Pharmaceuticals stock forecast: Based on 5 Wall Street analysts` predicted price targets for Regeneron Pharmaceuticals in the last 3 months, the avarage price target is $1,110, with a high forecast of $NaN. The average price target represents a 93.11% change from the last price of $574.79.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Regeneron Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Regeneron Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Evan David Seigerman BMO Capital | 25% 1/4 | 11 months ago | $1,190 107.03% upside | $843.6 | StreetInsider | Previous targets (3) |
Christopher Raymond Piper Sandler | 0% 0/1 | 11 months ago | $1,195 107.90% upside | $843.6 | StreetInsider | Previous targets (0) |
Andrew Berens Leerink Partners | 0% 0/2 | 11 months ago | $880 53.09% upside | $843.6 | StreetInsider | Previous targets (1) |
Cory Kasimov Evercore ISI | 0% 0/3 | 11 months ago | $1,170 103.55% upside | $838.2 | StreetInsider | Previous targets (2) |
Cory Kasimov Evercore ISI | 0% 0/3 | 11 months ago | $1,175 104.42% upside | $941.39 | StreetInsider | Previous targets (2) |
Mohit Bansal Wells Fargo | 50% 1/2 | 11 months ago | $1,050 82.67% upside | $962.34 | StreetInsider | Previous targets (1) |
Salveen Richter Goldman Sachs | 50% 1/2 | about 1 year ago | $1,292 124.77% upside | $1,091.98 | StreetInsider | Previous targets (1) |
David Risinger Leerink Partners | 0% 0/1 | about 1 year ago | $1,077 87.37% upside | $1,091.98 | TheFly | Previous targets (0) |
Thomas Klee Truist Financial | 0% 0/1 | about 1 year ago | $1,200 108.77% upside | $1,091.98 | TheFly | Previous targets (0) |
Brian Skorney Robert W. Baird | 0% 0/1 | about 1 year ago | $940 63.53% upside | $1,091.98 | StreetInsider | Previous targets (0) |
Evan David Seigerman BMO Capital | 25% 1/4 | about 1 year ago | $1,300 126.16% upside | $1,159.95 | StreetInsider | Previous targets (3) |
Brian Abrahams RBC Capital | 0% 0/7 | about 1 year ago | $1,282 123.03% upside | $1,139.41 | TheFly | Previous targets (6) |
Christopher Raymond Raymond James | 0% 0/3 | about 1 year ago | $1,242 116.07% upside | $1,187.66 | TheFly | Previous targets (2) |
Geoff Meacham Bank of America Securities | 0% 0/1 | about 1 year ago | $805 40.05% upside | $1,077.48 | TheFly | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/7 | about 1 year ago | $1,240 115.73% upside | $1,093.14 | TheFly | Previous targets (6) |
Christopher Raymond Raymond James | 0% 0/3 | about 1 year ago | $1,166 102.85% upside | $1,063.6 | StreetInsider | Previous targets (2) |
Yatin Suneja Guggenheim | 0% 0/1 | about 1 year ago | $1,180 105.29% upside | $1,085.62 | TheFly | Previous targets (0) |
Trung Huynh UBS | 0% 0/1 | about 1 year ago | $1,250 117.47% upside | $1,092.31 | TheFly | Previous targets (0) |
Terence Flynn Morgan Stanley | 0% 0/1 | about 1 year ago | $1,182 105.64% upside | $1,071.12 | TheFly | Previous targets (0) |
Jasper Hellweg Argus Research | 50% 1/2 | over 1 year ago | $1,170 103.55% upside | $1,063.89 | TheFly | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/7 | over 1 year ago | $1,299 125.99% upside | $1,022.03 | Benzinga | Previous targets (6) |
Brian Abrahams RBC Capital | 0% 0/7 | over 1 year ago | $1,229 113.81% upside | $1,010.54 | TheFly | Previous targets (6) |
Brian Abrahams RBC Capital | 0% 0/7 | over 1 year ago | $1,200 108.77% upside | $998.64 | StreetInsider | Previous targets (6) |
Evan David Seigerman BMO Capital | 25% 1/4 | over 1 year ago | $1,082 88.24% upside | $992.47 | StreetInsider | Previous targets (3) |
Christopher Raymond Raymond James | 0% 0/3 | over 1 year ago | $1,000 73.97% upside | $982.29 | StreetInsider | Previous targets (2) |
Cory Kasimov Evercore ISI | 0% 0/3 | over 1 year ago | $1,150 100.07% upside | $976.96 | StreetInsider | Previous targets (2) |
Brian Abrahams RBC Capital | 0% 0/7 | over 1 year ago | $1,185 106.16% upside | $937.61 | StreetInsider | Previous targets (6) |
Akash Tewari Jefferies | 66.67% 2/3 | over 1 year ago | $1,060 84.41% upside | $911.78 | StreetInsider | Previous targets (2) |
Brian Abrahams RBC Capital | 0% 0/7 | over 1 year ago | $1,189 106.85% upside | $921.34 | StreetInsider | Previous targets (6) |
Matthew Harrison Morgan Stanley | 75% 3/4 | over 1 year ago | $1,115 93.98% upside | $965.47 | StreetInsider | Previous targets (3) |
Brian Abrahams BMO Capital | 0% 0/1 | over 1 year ago | $1,076 87.19% upside | $934.06 | Benzinga | Previous targets (0) |
Andrew Berens Leerink Partners | 0% 0/2 | over 2 years ago | $976 69.80% upside | $820 | StreetInsider | Previous targets (1) |
Akash Tewari Jefferies | 66.67% 2/3 | over 2 years ago | $925 60.92% upside | $819.68 | StreetInsider | Previous targets (2) |
Unknown EF Hutton | N/A | over 2 years ago | $853 48.40% upside | $769.94 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 2 years ago | $834 45.09% upside | $783.13 | Benzinga | N/A |
Unknown Guggenheim | N/A | almost 3 years ago | $915 59.18% upside | $707.63 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | almost 3 years ago | $970 68.75% upside | $726.93 | Benzinga | N/A |
Unknown Canaccord Genuity | N/A | about 3 years ago | $750 30.48% upside | $710.21 | Benzinga | N/A |
Unknown Piper Sandler | N/A | about 3 years ago | $775 34.83% upside | $701.15 | Benzinga | N/A |
Unknown Wells Fargo | N/A | about 3 years ago | $800 39.18% upside | $718.83 | Benzinga | N/A |
Parker Lane Stifel Nicolaus | 100% 1/1 | about 3 years ago | $13 -97.73% downside | $708.85 | Benzinga | Previous targets (0) |
Unknown Barclays | N/A | about 3 years ago | $815 41.79% upside | $708.85 | Benzinga | N/A |
Matthew Harrison Morgan Stanley | 75% 3/4 | about 3 years ago | $851 48.05% upside | $708.85 | TheFly | Previous targets (3) |
Akash Tewari Jefferies | 66.67% 2/3 | about 3 years ago | $675 17.43% upside | $708.85 | TheFly | Previous targets (2) |
Matthew Harrison Morgan Stanley | 75% 3/4 | about 3 years ago | $625 8.73% upside | $628.71 | Pulse 2.0 | Previous targets (3) |
Unknown BMO Capital | N/A | about 3 years ago | $788 37.09% upside | $614.96 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | about 3 years ago | $625 8.73% upside | $618.54 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | about 3 years ago | $619 7.69% upside | $604.3 | Benzinga | N/A |
Kennen MacKay RBC Capital | 100% 2/2 | about 3 years ago | $638 10.99% upside | $597.62 | Pulse 2.0 | Previous targets (1) |
Mohit Bansal Wells Fargo | 50% 1/2 | over 3 years ago | $735 27.87% upside | $571.81 | Pulse 2.0 | Previous targets (1) |
Regeneron Pharmaceuticals Financial Estimates
Regeneron Pharmaceuticals Revenue Estimates
Regeneron Pharmaceuticals EBITDA Estimates
Regeneron Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $16.07B N/A | $12.17B -24.25% | $13.11B 7.75% | Avg: $14.93B Low: $13.91B High: $15.57B avg. 13.87% | Avg: $16.03B Low: $15.14B High: $17.03B avg. 7.37% | Avg: $17.24B Low: $16.27B High: $18.31B avg. 7.52% | Avg: $18.33B Low: $17.31B High: $19.47B avg. 6.33% |
Net Income
% change YoY
| $8.07B N/A | $4.33B -46.27% | $3.95B -8.86% | Avg: $4.45B Low: $3.58B High: $5.12B avg. 12.79% | Avg: $5.21B Low: $4.37B High: $6.96B avg. 17.02% | Avg: $6.68B Low: $6.19B High: $7.22B avg. 28.07% | Avg: $7.28B Low: $6.75B High: $7.87B avg. 8.96% |
EBITDA
% change YoY
| $9.38B N/A | $5.17B -44.86% | $4.69B -9.27% | Avg: $6.38B Low: $5.94B High: $6.65B avg. 35.96% | Avg: $6.85B Low: $6.46B High: $7.27B avg. 7.37% | Avg: $7.36B Low: $6.95B High: $7.82B avg. 7.52% | Avg: $7.83B Low: $7.39B High: $8.32B avg. 6.33% |
EPS
% change YoY
| $76.4 N/A | $40.51 -46.97% | $37.05 -8.54% | Avg: $37.85 Low: $31.57 High: $45.07 avg. 2.14% | Avg: $45.39 Low: $38.51 High: $61.22 avg. 19.94% | Avg: $58.78 Low: $54.5 High: $63.53 avg. 29.49% | Avg: $64.05 Low: $59.38 High: $69.23 avg. 8.96% |
Operating Expenses
% change YoY
| $4.68B N/A | $5.61B 19.86% | $7.25B 29.11% | Avg: $2.62B Low: $2.44B High: $2.74B avg. -63.77% | Avg: $2.82B Low: $2.66B High: $2.99B avg. 7.37% | Avg: $3.03B Low: $2.86B High: $3.22B avg. 7.52% | Avg: $3.22B Low: $3.04B High: $3.42B avg. 6.33% |
FAQ
What is Regeneron Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.71% in 2025-2028.
We have gathered data from 16 analysts. Their low estimate is 3.58B, average is 4.45B and high is 5.12B.
What is Regeneron Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.77% in 2025-2028.
We have gathered data from 20 analysts. Their low revenue estimate is $13.91B, average is $14.93B and high is $15.57B.
What is Regeneron Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.13% in 2025-2028.
We have gathered data from 16 analysts. Their low earnings per share estimate is $31.57, average is $37.85 and high is $45.06.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering Regeneron Pharmaceuticals stock. The most successful analyst is Evan David Seigerman whose win rate is 25%. He has correctly predicted 1/4 price targets.